Kadmon Holdings, Inc. (NYSE:KDMN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02
Departure of Directors or Certain Officers
On December 26, 2018, Bart M. Schwartz, Esq. notified Kadmon Holdings, Inc. (the “Company”) of his resignation as a member of the Board of Directors of the Company (the “Board”), effective as of the close of business on December 31, 2018. Mr. Schwartz serves as the Chairman of the Board, as the Chairman of the compensation committee of the Board and on the nominating and corporate governance committee and the regulatory and compliance committee of the Board. Mr. Schwartz is resigning due to increasing responsibilities at his charitable commitments, including the All Stars Project, a national youth non-profit organization where he serves as director and was recently elected chairman of its New York board, and the Police Athletic League, New York City’s largest independent youth development non-profit organization, where he serves as director. Mr. Schwartz has confirmed that his resignation is not the result of any disagreement with the Company. The Company thanks him for his service and wishes him well in his future endeavors.
|
Item 5.02 |
Regulation FD Disclosure |
On December 27, 2018, the Company issued a press release announcingMr. Schwartz’s resignation.
The information in this Item 5.02, including Exhibit 99.1 hereto, is being “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of Section 18 of the Exchange Act. The information in this Item 5.02 shall not be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended, or into any filing or other document to the Exchange Act, except as otherwise expressly stated in any such filing.
The full text of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
|
Item 5.02 |
Financial Statements and Exhibits. |
(d) Exhibits
Kadmon Holdings, Inc. Exhibit
EX-99.1 2 kdmn-20181226xex99_1.htm EX-99.1 991 Board Chairman Resignation Exhibit 99.1 Kadmon Chairman Bart M. Schwartz to Step Down from Board NEW YORK,…
To view the full exhibit click here
About Kadmon Holdings, Inc. (NYSE:KDMN)
Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company’s other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company’s portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson’s disease.